amgen chief marketing officer

Ms. Pineda was selected as a member of our board of directors to bring her expertise in government relations and regulatory oversight, corporate governance and human resources matters. Published May 05, 2022. Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). Mr. Fleischer currently serves as a director of The Clorox Company and Americans for Oxford, Inc. Mr. Fleischer was selected to join our board of directors due to his broad financial and international business perspective developed over many years in the private equity and investment banking industries. Based on an average daily trading volume, of 267,600 shares, the days-to-cover ratio is presently 5.1 days. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Evan Lippman joined Alnylam in September of 2022 as Chief Corporate Development and Strategy Officer bringing with him many years of experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies. He has worked across multiple geographies including the U.S., Europe, and emerging markets and in a broad range of small and large disease therapy areas. AtriCure does not currently pay a dividend. Neil Mitra is an innovator and entrepreneur with a passion for inventing biomedical devices. As of October 15th, there was short interest totaling 1,360,000 shares, a decrease of 15.5% from the September 30th total of 1,610,000 shares. Prior to Ippolita, Ms. Beraud was Executive Vice President for Tiffany & Co., with responsibility for its Global Retail Operations and oversight of strategic store development and real estate from October 2014 until June 2015. Builds and fosters relationships with medical and clinical communities, including the development of indication-specific Clinical Advisory Committees and other forms of strategic consultation. Earnings per share of Prior to that, Ms. Beraud served as President of Starbucks/Lipton Joint Ventures and Chief Marketing Officer of PepsiCo Americas Beverages from July 2009 to June 2011, and PepsiCos Global Chief Marketing Officer from December 2008 to July 2009. Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. She is currently a director of Frontier Group Holdings, Inc., Omnicom Group Inc., Chairwoman Emeritus and a board member of the Latino Corporate Directors Association and a member of the board of trustees of Earthjustice. Ensures the identification, recruitment and selection of appropriate clinical investigators and contract research organizations, resulting in appropriate negotiation of contracts. AtriCure has received a consensus rating of Buy. During this period, Ms. Pineda also served as General Counsel and Group Vice President of Administration from 2006 to 2008 and as Group Vice President of Corporate Communications and General Counsel from 2004 to 2006. Kelley is a member of the Healthcare Business Womens Association (HBA), the Human Resources Leadership Forum (HRLF) and the Corporate Executive Board (CEB). Das Biotechnologieunternehmen Amgen wurde 1980 als AMGen (Applied Molecular Genetics) gegrndet.Amgen ist mit ca. According to its website, Relativity Space is "building the first autonomous rocket factory and launch services for satellites" and "disrupting 60 years of aerospace.". Since then, ATRC stock has decreased by 41.9% and is now trading at $40.40. High institutional ownership can be a signal of strong market trust in this company. Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more Christopher McCormick, a director since 2016, was President and Chief Executive Officer of L.L. T-Mobile US, Inc. is an American wireless network operator headquartered in Bellevue, Washington, U.S. Its largest shareholder is a multinational telecommunications company Deutsche Telekom AG, which as of August 2022, holds 48.4 percent of the common stock. Bean, he was Senior Vice President and Chief Marketing Officer from 2000 to 2001. November 3, 2022|americanbankingnews.com. Bean, Inc. from 2001 until 2016. He previously served on the board of directors for VF Corporation, the Singapore Economic Development Board and was a member of the US-ASEAN Business Council, Singapore. Mr. Alstead currently serves as a director of Harley-Davidson, Inc., Array Technologies, and OYO Global. Privacy Policy. She was honored with the Healthcare Business Womens Association Rising Star award in 2013. During his time there, he led business units in Asia, Europe and the United States. Former President of Plan Operations and Chief Operating Officer of Health Care Service Corporation; former President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota; Director of Myriad Genetics. Intel's Autonomous Unit Mobileye Files U.S. IPO, Defying Weak Market Conditions. Should I buy or sell AtriCure stock right now? Piyush Sharma joined Alnylam as Chief Ethics & Compliance Officer in August 2022. Before her time at Abiomed, Kelley spent 10 years at Shire where she held a variety of roles across HR, eventually becoming Vice President and Head of Human Resources for Technical Operations and then Shires Corporate Divisions. The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[12] followed by Kevin W. Sharer in 2000. Papers from more than 30 days ago are available, all the way back to 1881. Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development, and commercialization. Prior experience at senior levels working in and/or leading cross-functional teams. 2019. He leads a team accountable for all aspects of CMC development, clinical and commercial product manufacturing and supply, enterprise GxP Quality oversight and facilities and engineering operations globally. He was the strategic leader of the Immunoscience franchise and oversaw the development of multiple clinical assets across the areas of rheumatology, gastroenterology, nephrology, and transplantation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy. Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash.. Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer, was promoted to President and COO in 2020, and was appointed as a Director and Chief Executive Officer in late 2021. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Bigelow, Express, Henri Bendel and Limited Stores. Amgen sponsored the Tour of California from 2011 to 2017. Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities. Prior to Shire, Kelley was a Principal Consultant at Clockwork Consulting (a pharmaceutical recruitment firm) and worked at Syntonix Pharmaceuticals (acquired by Biogen) and Digitas. [6][7] Amgen's Thousand Oaks staff in 2017 numbered 5,125 (7.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. According to analysts' consensus price target of $60.17, AtriCure has a forecasted upside of 48.9% from its current price of $40.40. By. Bean, Inc. from 2001 until 2016. During the same period last year, the company earned ($0.11) EPS. THOUSAND OAKS, Calif., Nov. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. The company was incorporated in 2000 and is headquartered in Mason, Ohio. Ensures that all clinical trials are in keeping with approved timelines and budgets, with potential obstacles identified and solutions implemented to avoid delays in clinical trial implementation. Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Founding Director of McGovern Institute for Brain Research, MIT; Nobel Laureate; Founder of Alnylam; Co-founder and former Director of Biogen; Member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences; Director of Syros Pharmaceuticals and Vir Biotechnology. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis. There are currently 4 buy ratings for the stock. MD with Board Certification in Oncology strongly preferred. ChemoCentryx is the maker of. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response. View institutional ownership trends. Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. Specifically, they have bought $0.00 in company stock and sold $229,168.00 in company stock. The company issued revenue guidance of $328-$333 million, compared to the consensus revenue estimate of $328.61 million. Prior to joining us, Mr. Bergh held a progression of leadership roles during his 28-year career at Procter & Gamble. 6H ago 05:37 Ms. Pineda was selected as a member of our Board of Directors to bring her expertise in government relations and regulatory oversight, corporate governance and human resources matters. 326 E 8th St #105, Sioux Falls, SD 57103 | [emailprotected] | (844) 978-6257 Mr. Alstead previously held the positions of Group President, Chief Financial Officer and Chief Administrative Officer of Starbucks, and a number of operational, general management and finance roles throughout the years. Seit 1983 ist Amgen unter dem Symbol AMGN an der US-amerikanischen Technologiebrse The company provided earnings per share (EPS) guidance of ($1.10)-($1.12) for the period, compared to the consensus estimate of ($1.10). In September, the company announced it would purchase the rights to. [11], The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). Facebook Jill Beraud, a director since 2013, most recently served as Chief Executive Officer of Ippolita, a privately-held luxury jewelry company with distribution in high-end department stores, flagship and eCommerce, from October 2015 until September 2018. Prior to joining Alnylam, Jeff served as Chief Financial Officer at Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the US. StockTwits All rights reserved. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. By using our website, you declare yourself in agreement with our use of cookies. The medical device company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $2.39. Before his time at Alexion, Piyush led anti-corruption compliance at Cognizant Technology Solutions and at Hess Corporation. 2017. Senior Advisor to the healthcare team of New Enterprise Associates; former Executive Vice President and Director of Bristol-Myers Squibb, where he also served as Chief Scientific officer and President of R&D; Co-chair of the Scientific Advisory Board of Amgen; Member of Scientific Steering Committee for the Sean Parker Institute for Cancer Immunotherapy and member of the Board of Directors for Adaptimmune, Vir Biotechnology and Surface Oncology. Nathan Reiff. Top institutional investors include Fiera Capital Corp (1.51%), Granite Investment Partners LLC (0.88%), Emerald Mutual Fund Advisers Trust (0.75%), Peregrine Capital Management LLC (0.45%), WCM Investment Management LLC (0.41%) and Rothschild & Co. Asset Management US Inc. (0.18%). During his tenure at Shire, Jeff also led Shires rare disease US, LATAM, and Asia Pacific commercial operations, as well as Shires global rare disease business unit. What guidance has AtriCure issued on next quarter's earnings? Ms. Beraud was selected to join our board of directors due to her extensive marketing, social media and consumer branding experience, as well as her extensive managerial and operational knowledge in the apparel and other consumer goods industries. Previously, Ms. Pineda served Toyota Motor North America as Group Vice President of National Philanthropy and the Toyota USA Foundation from 2004 to 2013. Receive ATRC Stock News and Ratings via Email, November 4, 2022|americanbankingnews.com. Ellen is co-chair of the Paradigm for Parity coalition and a board director of Dell Technologies, Amgen, and Goldman Sachs. AtriCure has a P/B Ratio of 4.17. Ms. Ming joined The Gap, Inc. in 1986, serving in various executive capacities at its San Francisco headquarters, and in 1994, she was a member of the executive team who launched Old Navy. site, you agree to their use. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure. [54] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe[55] and Japan. The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list): Ronald Vogel. Board Software. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA. The drug was approved in 2021 with a list price of $17,900 per month. View ATRC analyst ratings or view top-rated stocks. The Alnylam Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization, and strategy to our efforts in developing RNAi (RNA interference) therapeutics. Identify stocks that meet your criteria using seven unique stock screeners. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. Managing Partner, Polaris Partners; Co-founder, Executive Chair, and former Chief Executive Officer of Lyndra Therapeutics; Executive Chair of SQZ Biotech; Senior Lecturer at Harvard Business School; former Executive Vice President and General Counsel of Pfizer; served as the Business Unit Lead for Pfizer Consumer Healthcare. AtriCure has only been the subject of 2 research reports in the past 90 days. He is a Fellow of the Royal College of Physicians, U.K. Akshay is a member of the Board of Directors for Editas Medicine Inc. and Scholar Rock Inc. From 2014-2018, he served as a Board member of Visterra, Inc. Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. This represents a modest decline of 1% year-over-year. [53] In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares. Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Get short term trading ideas from the MarketBeat Idea Engine. Prior to Alexion, Al spent over eight years with Bristol-Myers Squibb, overseeing fermentation and biocatalysis development, technology transfer and commercial manufacturing support of biologics products. How were AtriCure's earnings last quarter? CRC Press, 2007. By. Mr. Prime was selected to join our board of directors due to his broad professional experience, including with our company, and his additional insight arising from his familial connection to our founder. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy. What is Michael Carrel's approval rating as AtriCure's CEO? Jenny Ming, a director since 2014, was President and Chief Executive Officer of Charlotte Russe Inc., a fast-fashion specialty retailer of apparel and accessories catering to young women, a position she held from October 2009 to February 2019. In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha). THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with Bean in 1983, previously serving in a number of senior and executive level positions in advertising and marketing. Pharmaceutical industry experience in the successful development of new drug products is strongly preferred. Academics from across the U.S. write to President Biden urging him to take action against the Iranian regime. Our website is made possible by displaying online advertisements to our visitors. The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media. We use cookies and similar technologies on our website and by clicking "Accept" or continuing to use this View our full suite of financial calendars and market data tables, all for free. from the University of California, San Francisco. Mr. McCormick is a director of Big Lots!, Inc and serves as Committee Chair for its Capital Allocation & Planning Committee. AtriCure had a negative net margin of 17.76% and a negative trailing twelve-month return on equity of 12.09%. Prior to joining Alnylam, Indrani served as Executive Vice President, Chief Compliance Officer at Alexion, and was a member of the executive team. Dr. Garg is a member of the Board of Directors of SQZ Biotechnologies (SQZ). [13] Robert A. Bradway became Amgens president and chief executive officer in May 2012 following Sharer's retirement.[14]. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Senior Advisor at Blackstone Group; former Chief Executive Officer and Director of Sanofi; former Chief Executive Officer and Chair of Bayer HealthCare, former President and General Manager of the Emerging Markets and Established Products business units; member of the Executive Leadership Team of Pfizer Inc. Former Chief Financial Officer of Millennium Pharmaceuticals; Chair of the Board of Directors of Cyclerion Therapeutics; Director of Syros Pharmaceuticals and Forma Therapeutics. Chief Executive Officer of Alnylam; member of the Board of Directors of Pacira BioSciences, Inc., and The American Funds; Scientific Advisory Committee of the Bill and Melinda Gates Foundation; member of the Discovery Council of Harvard Medical School; member of Biotechnology Industry Organization Health Section Governing Board. Mr. Friedman is also involved in many institutional, academic, philanthropic and not-for-profit boards, including the San Francisco Planning and Urban Research Association, the University of California, Berkeley Foundation, the Jewish Home of San Francisco and Build Change. 11.2 Academics Letter to Biden on Iran protests - Free download as PDF File (.pdf), Text File (.txt) or read online for free. Receive news and updates on the work at Alnylam that affects you most. In Q3, we recognized total revenue of $6.7 billion. View our ATRC earnings forecast. Cytotoxics and High Potency Manufacturing, AI In Unexpected Places: How ML And NLP Improve Startup Timelines, Lonza Enters Collaboration Agreement With Singzyme, How To Successfully Leverage Real World Data And Prove Its Value To Stakeholders, Global Pharma Confidence Hits Record High, Narrowing Healthcares Sustainability Gap, Streamlining Early Phase Discovery and Development, Comprehensive Bioanalysis of ADCs in DMPK Studies, Trends Toward Outsourcing Buffer Manufacturing, Latest Breaking News From Nutraceuticals World, Nutrameltz Launches Delivery Technology in North America, Pharmaceutical Study Compares Low-Dose Statin to Dietary Supplements, Geno Launches Ingredient Formulated to Raise Ketone Levels, USGBC, IWBI Strengthen Strategic Partnership to Accelerate Sustainable Buildings, Mankiewicz Reveals its Colors of the Year 2023, Hempel Aims to Move Needle Towards a Decarbonised Future at COP27, Latest Breaking News From Medical Product Outsourcing, Anumana Acquires NeuTrace to Advance Electrophysiology Deep Learning, NeuroMetrix Strategically Launches Quell Fibromyalgia Device, Latest Breaking News From Contract Pharma, Latest Breaking News From Beauty Packaging, Peace Out Skincare Receives $20 Million Investment, The Este Lauder Companies Shares 2022 Social Impact and Sustainability Report. A proven success record in Phase I-IV clinical research studies and trial design as well as the successful submission of INDs and marketing approval-directed filings (BLAs, NDAs, and MAAs). Excellent knowledge of the competitive environment for drugs in the Oncology marketplace and in research and development pipelines. Prior to Tiffany & Co., Ms. Beraud was with Living Proof, Inc., a privately-held company that uses advanced medical and materials technologies to create hair care and skin care products for women, where she was Chief Executive Officer from December 2011 to October 2014. Indrani Franchini joined Alnylam in January 2022 and has over 20 years of global legal experience in a variety of legal and compliance roles. Opens New Distribution Center in Dublin, Ireland, Application of Risk-Based Approach in a ATMPs Multi-Product Facility, Contract Pharma Q&A with Jeffrey Speicher of Avma Pharma Solutions, Stevanato Group and Gerresheimer AG Unveil EZ-fill Smart, Steriline Presents Robotics and Isolators for Nest and Bulk Filling, Aphena Completes $20M Tennessee Expansion, Packaging Today's Specialized Drug Products, CSafe, BioLife Solutions Enter CGT Supply Chain Solutions Pact, AI in Unexpected Places: How ML and NLP Improve Startup Timelines, How to Successfully Leverage Real World Data and Prove its Value to Stakeholders, Altasciences Los Angeles Clinical Site Receives CAP Accreditation, Cambrex to Invest $16.5M in New R&D Facility and Expansion, Samsung Biologics Obtains Two International Information Security Certifications. Prior to Alexion, Indrani spent five years in legal and compliance roles functioning as Chief Compliance Officer and Assistant Corporate Secretary for Hess Corporation, a Fortune Global 500 leader in oil and gas exploration and production. Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. 20th Annual Spine, Orthopedic & Pain Management-Driven ASC Conference, LeanTaaS Transform Hospital Operations Virtual Summit, Beckers Digital Health + Health IT Podcast, Becker's Ambulatory Surgery Centers Podcast, Becker's Cardiology + Heart Surgery Podcast, Current Issue - Becker's Clinical Leadership & Infection Control, Past Issues - Becker's Clinical Leadership & Infection Control, 150 top places to work in healthcare | 2022, 75 black healthcare leaders to know| 2022, 50 chief digital officer innovators to know | 2022, 260+ healthcare revenue cycle management companies to know | 2022, 83 community hospital ceros to know | 2022, 50 community hospital cfos to know | 2022, Becker's Health IT + Digital Health + RCM, ASC Annual Meeting: The Business and Operations of ASCs. AtriCure, Inc. (NASDAQ:ATRC) issued its earnings results on Wednesday, November, 3rd. Copyright 2022 Alnylam Pharmaceuticals, Inc. All Rights Reserved, Chief Medical Officer and EVP, Development & Medical Affairs, Chief Technical Operations and Quality Officer, Chief Corporate Development & Strategy Officer. Billions could be poured into exploration companies searching for new U.S. deposits. Attracts, manages, and retains top talent on the Clinical Development team, which may include Medical/Clinical Science, Clinical Operations, Biostatistics/Data Management, Pharmacovigilance, Regulatory Affairs, GCP Compliance, Clinical Pharmacokinetics and Medical Affairs. In this position he was responsible for developing, structuring, and negotiating global acquisitions, divestments, and commercially focused licensing/strategic collaborations. Real-time analyst ratings, insider transactions, earnings data, and more. 95.21% of the stock of AtriCure is held by institutions. Mr. Alstead brings to our board of directors his broad financial and business perspective developed over many years in the global consumer goods industry. Mr. Prime is the Partner, Idea Generation and Research, at Indaba Capital Management, L.P., where he has served since its founding in 2010. Cookies help us to provide you with an excellent service. Represents and manages the companys clinical programs to diverse audiences including: FDA or EMEA, shareholders, corporate partners, Board of Directors and other key stakeholders. Amgen engages with the public and private sectors in a variety of settings including to promote research and development, academic funding, event sponsorship, philanthropy, and political lobbying. He is also a former director of Sun Life Financial, Inc. Mr. McCormick brings to our board of directors his deep channel knowledge and eCommerce and direct marketing experience. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Aws Lambda Default Credentials, Bhakra Dam Water Level Today, Pronunciation Of Espresso, November Important Days 2022, Aakash Test Series 2023, Santa Maria Restaurant Menu,